Literature DB >> 33074353

Uric acid drives intestinal barrier dysfunction through TSPO-mediated NLRP3 inflammasome activation.

Qiulan Lv1, Daxing Xu1, Jinfeng Ma1, Yan Wang1, Xiaomin Yang1, Peng Zhao1, Liang Ma1, Zhiyuan Li1, Wan Yang1, Xiu Liu1, Guanpin Yang2, Shichao Xing3,4.   

Abstract

BACKGROUND AND AIM: Intestinal epithelial dysfunction is the foundation of various intestinal and extra-intestinal diseases, while the effects and mechanism of uric acid on the intestinal barrier are little known. TSPO has been shown to be related to the generation of ROS and is involved in regulating inflammation, whether uric acid drives intestinal epithelial dysfunction through TSPO-mediated NLRP3 inflammasome activation is unknown.
METHODS: UOX gene knockout mouse (UOX-/-) were used for models of hyperuricemia. Fluorescein isothiocyanate (FITC)-labeled dextran was used to assess in vivo intestinal permeability. Serum lipopolysaccharide (LPS) and culture supernatants IL-1β were measured using ELISA Kit. IEC-6 exposed to different concentrations of uric acid was used for in vitro experiment. Protein content and mRNA were assessed using Western blotting and Q-PCR, respectively. Intracellular ROS was determined using flow cytometry and fluorescence microscope. Mitochondrial membrane potential was detected on an immunofluorescence. Small interfering RNA transfection was used to assess the interaction between translocator protein (TSPO) and NLRP3 inflammasome. N-acetyl-L-cysteine (NAC) was used as ROS scavenger.
RESULTS: Our results showed that hyperuricemia mice were characteristic by increased intestinal permeability. Hyperuricemia upregulated TSPO, increased production of ROS and activated NLRP3 inflammasome, which resulted in lower expression of occludin and claudin-1. In vitro, we showed that soluble uric acid alone increased the expression of TSPO, depolarized mitochondrial membrane potential, increased ROS release and activated NLRP3 inflammasome, which further reduced the expression of occludin and claudin-1. Silencing TSPO suppressed NLRP3 inflammasome activation and increased expression of claudin-1 and occludin, which was accompanied by lower levels of ROS. Scavenging ROS also significantly inhibited NLRP3 inflammasome activation without change of TSPO, indicating that TSPO-mediated NLRP3 inflammasome activation was dependent on ROS.
CONCLUSIONS: In conclusion, uric acid drives intestinal barrier dysfunction through TSPO-mediated NLRP3 inflammasome.

Entities:  

Keywords:  Intestinal epithelial barrier; NLRP3 inflammasome; TSPO; Uric acid

Year:  2020        PMID: 33074353     DOI: 10.1007/s00011-020-01409-y

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  38 in total

Review 1.  The intestinal epithelial barrier: a therapeutic target?

Authors:  Matthew A Odenwald; Jerrold R Turner
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-11-16       Impact factor: 46.802

2.  Targeting the NLRP3 inflammasome in inflammatory diseases.

Authors:  Matthew S J Mangan; Edward J Olhava; William R Roush; H Martin Seidel; Gary D Glick; Eicke Latz
Journal:  Nat Rev Drug Discov       Date:  2018-08-17       Impact factor: 84.694

3.  K⁺ efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter.

Authors:  Raúl Muñoz-Planillo; Peter Kuffa; Giovanny Martínez-Colón; Brenna L Smith; Thekkelnaycke M Rajendiran; Gabriel Núñez
Journal:  Immunity       Date:  2013-06-27       Impact factor: 31.745

4.  Hyperglycemia drives intestinal barrier dysfunction and risk for enteric infection.

Authors:  Christoph A Thaiss; Maayan Levy; Inna Grosheva; Danping Zheng; Eliran Soffer; Eran Blacher; Sofia Braverman; Anouk C Tengeler; Oren Barak; Maya Elazar; Rotem Ben-Zeev; Dana Lehavi-Regev; Meirav N Katz; Meirav Pevsner-Fischer; Arieh Gertler; Zamir Halpern; Alon Harmelin; Suhail Aamar; Patricia Serradas; Alexandra Grosfeld; Hagit Shapiro; Benjamin Geiger; Eran Elinav
Journal:  Science       Date:  2018-03-08       Impact factor: 47.728

5.  Myosin IXB variant increases the risk of celiac disease and points toward a primary intestinal barrier defect.

Authors:  Alienke J Monsuur; Paul I W de Bakker; Behrooz Z Alizadeh; Alexandra Zhernakova; Marianna R Bevova; Eric Strengman; Lude Franke; Ruben van't Slot; Martine J van Belzen; Ineke C M Lavrijsen; Begoña Diosdado; Mark J Daly; Chris J J Mulder; M Luisa Mearin; Jos W R Meijer; Gerrit A Meijer; Erica van Oort; Martin C Wapenaar; Bobby P C Koeleman; Cisca Wijmenga
Journal:  Nat Genet       Date:  2005-11-13       Impact factor: 38.330

Review 6.  Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation.

Authors:  Sanjeev Mariathasan; Denise M Monack
Journal:  Nat Rev Immunol       Date:  2007-01       Impact factor: 53.106

7.  The DNA Inflammasome in Human Myeloid Cells Is Initiated by a STING-Cell Death Program Upstream of NLRP3.

Authors:  Moritz M Gaidt; Thomas S Ebert; Dhruv Chauhan; Katharina Ramshorn; Francesca Pinci; Sarah Zuber; Fionan O'Duill; Jonathan L Schmid-Burgk; Florian Hoss; Raymund Buhmann; Georg Wittmann; Eicke Latz; Marion Subklewe; Veit Hornung
Journal:  Cell       Date:  2017-10-12       Impact factor: 41.582

8.  Extra-renal elimination of uric acid via intestinal efflux transporter BCRP/ABCG2.

Authors:  Atsushi Hosomi; Takeo Nakanishi; Takuya Fujita; Ikumi Tamai
Journal:  PLoS One       Date:  2012-02-10       Impact factor: 3.240

9.  Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity.

Authors:  Jorge Henao-Mejia; Eran Elinav; Chengcheng Jin; Liming Hao; Wajahat Z Mehal; Till Strowig; Christoph A Thaiss; Andrew L Kau; Stephanie C Eisenbarth; Michael J Jurczak; Joao-Paulo Camporez; Gerald I Shulman; Jeffrey I Gordon; Hal M Hoffman; Richard A Flavell
Journal:  Nature       Date:  2012-02-01       Impact factor: 49.962

10.  Soluble Uric Acid Activates the NLRP3 Inflammasome.

Authors:  Tarcio Teodoro Braga; Maria Fernanda Forni; Matheus Correa-Costa; Rodrigo Nalio Ramos; Jose Alexandre Barbuto; Paola Branco; Angela Castoldi; Meire Ioshie Hiyane; Mariana Rodrigues Davanso; Eicke Latz; Bernardo S Franklin; Alicia J Kowaltowski; Niels Olsen Saraiva Camara
Journal:  Sci Rep       Date:  2017-01-13       Impact factor: 4.379

View more
  3 in total

1.  Folic acid and zinc improve hyperuricemia by altering the gut microbiota of rats with high-purine diet-induced hyperuricemia.

Authors:  Xuewei Sun; Jie Wen; Baosheng Guan; Jialin Li; Jincheng Luo; Jie Li; Mingyu Wei; Hongbin Qiu
Journal:  Front Microbiol       Date:  2022-07-29       Impact factor: 6.064

2.  The Additive Values of the Classification of Higher Serum Uric Acid Levels as a Diagnostic Criteria for Metabolic-Associated Fatty Liver Disease.

Authors:  Jie He; Junzhao Ye; Yanhong Sun; Shiting Feng; Youpeng Chen; Bihui Zhong
Journal:  Nutrients       Date:  2022-08-31       Impact factor: 6.706

Review 3.  Translocator Protein 18 kDa (TSPO) as a Novel Therapeutic Target for Chronic Pain.

Authors:  Jie Liu; Jingyao Huang; Zhenjiang Zhang; Rui Zhang; Zhihao Zhang; Yongxin Liu; Baoyu Ma
Journal:  Neural Plast       Date:  2022-08-29       Impact factor: 3.144

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.